Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.35M Sell
3,735
-61
-2% -$20.9K 0.3% 75
2026
Q1
$1.34M Buy
3,796
+112
+3% +$39.9K 0.33% 63
2025
Q4
$1.21M Buy
3,684
+14
+0.4% +$4.44K 0.3% 67
2025
Q3
$1.1M Sell
3,670
-250
-6% -$72.5K 0.28% 72
2025
Q2
$1.09M Buy
3,920
+30
+0.8% +$8.5K 0.3% 69
2025
Q1
$1.21M Sell
3,890
-411
-10% -$121K 0.37% 58
2024
Q4
$1.12M Buy
4,301
+15
+0.3% +$4.45K 0.34% 58
2024
Q3
$1.38M Buy
4,286
+657
+18% +$215K 0.42% 48
2024
Q2
$1.13M Sell
3,629
-183
-5% -$53.8K 0.37% 54
2024
Q1
$1.08M Buy
3,812
+885
+30% +$259K 0.39% 55
2023
Q4
$843K Sell
2,927
-31
-1% -$8.45K 0.34% 63
2023
Q3
$795K Buy
2,958
+81
+3% +$20.2K 0.35% 67
2023
Q2
$639K Sell
2,877
-102
-3% -$23.7K 0.28% 78
2023
Q1
$720K Buy
2,979
+226
+8% +$55.5K 0.33% 67
2022
Q4
$723K Buy
+2,753
New +$738K 0.38% 63

Other funds holding AMGN

Westmount Partners's AMGN Position: Q2 2026 in Review

Westmount Partners reduced its Amgen (AMGN) stake by 1.6% in Q2 2026, selling an estimated $20.9K and leaving 3,735 shares worth $1.35M. The position accounts for 0.3% of the portfolio, ranked #75.

Westmount Partners first reported a position in AMGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.38M in Q3 2024. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Westmount Partners held 3,735 shares of Amgen worth $1.35M as of Q2 2026.
  • Westmount Partners sold 61 Amgen shares in Q2 2026, an estimated $20.9K.
  • Amgen made up 0.3% of Westmount Partners's portfolio in Q2 2026, its #75 holding.
  • Westmount Partners first reported a position in Amgen in Q4 2022 and has held it in 15 quarters since.
  • Westmount Partners's Amgen position peaked at $1.38M in Q3 2024.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.